Avantor (NYSE:AVTR) Sets New 1-Year Low - Here's What Happened

Avantor, Inc. (NYSE:AVTR - Get Free Report) shares reached a new 52-week low during trading on Friday . The stock traded as low as $17.90 and last traded at $18.12, with a volume of 6265783 shares. The stock had previously closed at $18.05.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Raymond James reiterated an "outperform" rating and issued a $24.00 price objective (down from $26.00) on shares of Avantor in a research note on Monday, February 10th. Royal Bank of Canada reduced their price target on Avantor from $33.00 to $31.00 and set an "outperform" rating for the company in a research report on Monday, February 10th. Stifel Nicolaus decreased their price objective on Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. Wells Fargo & Company cut their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Finally, Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Avantor presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.92.

Avantor Trading Down 1.3 %

The stock has a market cap of $12.16 billion, a PE ratio of 38.84, a PEG ratio of 3.87 and a beta of 1.28. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The firm has a fifty day simple moving average of $21.44 and a two-hundred day simple moving average of $23.20.

Avantor (NYSE:AVTR - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the company earned $0.22 EPS. As a group, equities analysts expect that Avantor, Inc. will post 0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB lifted its stake in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company's stock worth $26,000 after purchasing an additional 625 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company's stock valued at $34,000 after buying an additional 830 shares in the last quarter. Global Retirement Partners LLC lifted its position in Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company's stock worth $52,000 after buying an additional 1,067 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock worth $53,000 after buying an additional 835 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in Avantor by 56.3% in the fourth quarter. UMB Bank n.a. now owns 2,981 shares of the company's stock worth $63,000 after buying an additional 1,074 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.